Back to search
FDAFDA · Food and drugs·Recall number D-0790-2020

Tri-Lo-Marzia (Norgestimate and Ethinyl Estradiol Tablets, USP), 0.180 mg/0.025 mg; 0.215mg/0.025 mg and 0.250 mg/0.025 mg, Pack size - 3 x 28's wallets/carton, Rx Only, Distributed by Lupin Pharmaceuticals, Inc, Baltimore MD 21202, Manufactured by: Lupin Limited, Pithampur, (M.P.)- 454775, India. NDC 68180-837-13 (3x28 carton ) NDC 68180-837-11 (28 tablet wallet)

Published January 22, 2020 · Recall initiated: January 10, 2020

Summary

FDA records drug Class III recall D-0790-2020, published January 22, 2020 and initiated January 10, 2020. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 34,080 boxes (3 wallets per carton, 80 cartons per box); Lot: Lot # L800498, exp. date February 2020. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Out of specification test result observed during retrospective review of blend uniformity test data.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Distributed nationwide in the US
Lot
Lot # L800498, exp. date February 2020
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tri-Lo-Marzia (Norgestimate and Ethinyl Estradiol Tablets, USP), 0.180 mg/0.025 mg; 0.215mg/0.025 mg and 0.250 mg/0.025 mg, Pack size - 3 x 28's wallets/carton, Rx Only, Distributed by Lupin Pharmaceuticals, Inc, Baltimore MD 21202, Manufactured by: Lupin Limited, Pithampur, (M.P.)- 454775, India. NDC 68180-837-13 (3x28 carton ) NDC 68180-837-11 (28 tablet wallet) recalled?

Yes. FDA published recall D-0790-2020 on January 22, 2020. Reported hazard: CGMP Deviations: Out of specification test result observed during retrospective review of blend uniformity test data.

What should I do if I have this product?

Voluntary: Firm initiated · Letter